Frontotemporal dementia (FTD)
About
FTD is the second most common early-onset dementia after Alzheimer's disease. About 30-40% of patients with FTD carry mutations in genes such as C9orf72, GRN, and MAPT. Unlike AD, FTD mainly presents as behavioral abnormalities or language disorders rather than memory loss. Core dilemmas: ① There is currently no FDA-approved disease-modifying therapy for FTD;②tau protein-targeted drugs have repeatedly failed in AD, and tau pathology in FTD is more prominent but also faces challenges;③ The disease progresses faster than AD.
Features & Symptoms
- Behavior abnormalities, language disorders, personality changes
- not memory decline.
- Death 6-10 years after onset
- About 30-40% of patients carry genetic mutations
Treatment Options
| Treatment | Description | Stage | Price Range |
|---|---|---|---|
| GRN gene replacement therapy | AAV vectors deliver normal GRN genes and restore levels of granulose protein precursors. FTD caused by GRN mutations is in the Phase I/II test stage. | Phase I/II | $500K - $1.5M/疗程 |
| Anti-TDP-43 immunotherapy | Monoclonal antibody that targets TDP-43 pathology. TDP-43 protein pathology is very common in FTD, especially in patients with C9orf72 and GRN mutations. | Phase I | $100K - $300K/年 |
| Comprehensive behavioral management + language rehabilitation | A comprehensive management plan for behavioral symptoms (deinhibition, compulsive behavior, apathy) and language disorders (progressive non-fluent aphasia, semantic dementia) in patients with FTD. | 临床应用 | $50K - $150K/年 |
Prognosis
Death 6-10 years after onset
Additional Notes
Notes: Genetic testing recommendations: It is recommended to perform gene testing for C9orf72, GRN, and MAPT. Carriers of GRN mutations can consider ongoing clinical trials of gene replacement therapy; behavioral management: Patients with behavioral variant FTD (bvFTD) often experience impulse control disorders and social misconduct, requiring joint psychiatric and neurology management; Speech rehabilitation: Patients with primary progressive aphasia (PPA) should start speech therapy and alternative communication training as soon as possible;ALS monitoring: Carriers of C9orf72 mutations are at risk of developing ALS and need to monitor muscle strength and electromyogram regularly; Caregiver support: Caregivers of FTD bear a heavy burden, and the platform can assist in arranging caregivers 'psychological support and breathing services. Exclusive service commitment: The platform will allocate a dedicated medical team to each patient to assist in dismantling and properly deploying the following precautions throughout the process. When cross-state and cross-border diagnosis and treatment projects or drugs are involved, the platform will make overall arrangements for the entire docking; for disabled and semi-disabled patient groups, the platform will provide rush-free alternative solutions (including remote consultation, door-to-door sampling, direct drug delivery in the cold chain, etc.), to ensure that patients can get the same high-quality diagnosis and treatment resources without having to travel in person.; Study phase: Phase I/II clinical. Prognosis: Death 6-10 years after onset.
Frequently Asked Questions
What is Frontotemporal dementia (FTD)?
FTD is the second most common early-onset dementia after Alzheimer's disease. About 30-40% of patients with FTD carry mutations in genes such as C9orf72, GRN, and MAPT. Unlike AD, FTD mainly presents as behavioral abnormalities or language disorders rather than memory loss. Core dilemmas: ① There is currently no FDA-approved disease-modifying therapy for FTD;②tau protein-targeted drugs have repeatedly failed in AD, and tau pathology in FTD is more prominent but also faces challenges;③ The disease progresses faster than AD.
What are the symptoms of Frontotemporal dementia (FTD)?
Behavior abnormalities, language disorders, personality changes,not memory decline.,Death 6-10 years after onset,About 30-40% of patients carry genetic mutations
How is Frontotemporal dementia (FTD) treated?
GRN gene replacement therapy: AAV vectors deliver normal GRN genes and restore levels of granulose protein precursors. FTD caused by GRN mutations is in the Phase I/II test stage.; Anti-TDP-43 immunotherapy: Monoclonal antibody that targets TDP-43 pathology. TDP-43 protein pathology is very common in FTD, especially in patients with C9orf72 and GRN mutations.; Comprehensive behavioral management + language rehabilitation: A comprehensive management plan for behavioral symptoms (deinhibition, compulsive behavior, apathy) and language disorders (progressive non-fluent aphasia, semantic dementia) in patients with FTD.
What is the prognosis for Frontotemporal dementia (FTD)?
Death 6-10 years after onset